Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment (vol 14, pg 2249, 2024)
Por:
Silverberg, JI, Wollenberg, A, Gold, LS, Del Rosso, J, Yosipovitch, G, Lio, P, Carrascosa, JM, Gallo, G, Ding, YX, Xu, ZH, Casillas, M, Pierce, E, Agell, H and Ständer, S
Publicada:
1 nov 2024
Ahead of Print:
1 oct 2024
Resumen:
Filiaciones:
Silverberg, JI:
George Washington Univ, Sch Med, Washington, DC 20052 USA
Wollenberg, A:
Univ Hosp Augsburg, Dept Dermatol & Allergy, Augsburg, Germany
Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany
UKSH Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany
Gold, LS:
Henry Ford Hlth Syst, Detroit, MI USA
Del Rosso, J:
JDR Dermatol Res, Las Vegas, NV USA
Yosipovitch, G:
Univ Miami, Miller Sch Med, Miami, FL USA
Lio, P:
Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias i Pujol, Serv Dermatol, Barcelona, Spain
Gallo, G:
Eli Lilly & Co, Indianapolis, IN USA
Ding, YX:
Eli Lilly & Co, Indianapolis, IN USA
Xu, ZH:
CIMS Global LLC, Somerset, NJ USA
Casillas, M:
Eli Lilly & Co, Indianapolis, IN USA
Pierce, E:
Eli Lilly & Co, Indianapolis, IN USA
Agell, H:
Almirall Prodesfarma, Barcelona, Spain
Ständer, S:
Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany
Univ Hosp Munster, Dept Dermatol, Munster, Germany
Green Submitted, gold
|